Lead Product(s): ALKS 4230
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
ALKS 4230 is an investigational, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the interleukin-2-induced activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex.